Bibliography
- Huang J, Wolk J, Gewitz MH, Mathew R. Progressive endothelial cell damage in an inflammatory model of pulmonary hypertension. Exp Lung Res 2010;36:57-66
- Schermuly RT, Dony E, Ghofrani HA, Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005;115:2811-21
- Mathew R. Cell-specific dual role of caveolin-1 in pulmonary hypertension. Pulm Med 2011;2011:573432
- Mathew R, Huang J, Katta UD, Immunosuppressant- induced endothelial damage and pulmonary arterial hypertension. J Pediatr Hematol Oncol 2011;33:55-8
- Rai PR, Cool CD, King JA, The cancer paradigm of severe pulmonary arterial hypertension. Am J Respir Crit Care Med 2008;178:558-64
- Perros F, Montani D, Dorfmuller P, Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2008;176:81-8
- Ghofrani HA, Morrell NW, Hoeper MM, Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care 2010;182:1173-7
- ten Freyhaus H, Dumitrescu D, Berghausen E, Imatinib mesylate for the treatment of pulmonary arterial hypertension. Expert Opin Investig Drugs 2012;21:(1):119-134
- Frenckner B, Broome M, Lindstrom M, Radell P. Platelet-derived growth factor inhibition—a new treatment of pulmonary hypertension in congenital diaphragmatic hernia? J Pediatr Surg 2008;43:1928-31
- Tapper EB, Knowles D, Heffron T, Portopulmonary hypertension: Imatinib s a novel treatment and the Emory experience with this condition. Transplant Proc 2009;41:1969-710
- Ten Freyhaus H, Dumitrescu D, Bovenschulte H, Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension. Clin Res Cardiol 2009;98:265-7
- Garcia Hernandez FJ, Castillo Palma MJ, Gonzalez Leon R, Experience with imatinib to treat pulmonary arterial hypertension. Arch Bronconeumol 2008;44:689-91
- Hatano M, Yao A, Shiga T, Imatinib mesylate has the potential to exert its efficacy by down-regulating the plasma concentrations of platelet-derived growth factor in patients with pulmonary arterial hypertension. Int Heart J 2010;51:272-6
- Liu Y, Ramirez J, Ratain MJ. Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitors. Br J Clin Pharmacol 2011;71:917-20
- Andrea J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008;22:1278-312
- Ball SG, Shuttleworth CA, Kietley CM. Vascular endothelial growth factor can signal through platelet-derived growth factor receptors. J Cell Biol 2007;177:489-500
- Hirai T, Masaki T, Kuratsune M, PDGF receptor tyrosine kinase inhibitor suppresses measngial cell proliferation involving STAT3 activation. Clin Exp Immunol 2006;144:353-61
- Peterson TE, Guicciardi ME, Gulati R, Caveolin-1 can regulate vascular smooth muscle cell fare by switching platelet-derived growth factor from a proliferative to an apoptotic pathway. Arterioscler Thromb Vasc Biol 2003;23:1521-7
- Yamamoto M, Toya Y, Ishikawa Y. Caveolin-1 is an inhibitor of platelet-derived growth factor receptor signaling. Exp Cell Res 1999;247:380-8
- Davis BN, Hilyard AC, Nguyen PH, Induction of microRNA-221 by platelet-derived growth factor signaling is critical for modulation of vascular smooth muscle phenotype. J Biol Chem 2009;284:3728-38
- Montani D, Perros F, Gambaryan N, c-kit positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2011;184:116-23